Search research articles
Contact Us
Filters
Showing results (121-130 of 141) with videos related to
Page
of 15
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 12, 2017
Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies
Zhong-Yi Dong, Chao Zhang, Yu-Fa Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 30, 2018
Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation
Shan Su, Zhong-Yi Dong, Zhi Xie, et al.
NPJ Precision Oncology
|
September 19, 2022
Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis
Chao Zhang, Hua-Fei Chen, Shi Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2025
Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer
Jia-Tao Zhang, Si-Yang Liu, Xuan Gao, et al.
JTO Clinical and Research Reports
|
January 6, 2025
Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for <i>EGFR</i>-Mutated NSCLC After Complete Resection
Song Dong, Bingfa Yan, Si-Yang Liu, et al.
Frontiers in Oncology
|
October 31, 2022
Deep learning-based growth prediction for sub-solid pulmonary nodules on CT images
Ri-Qiang Liao, An-Wei Li, Hong-Hong Yan, et al.
Annals of Nuclear Medicine
|
December 25, 2023
Impact of preoperative [<sup>18</sup>F]FDG PET/CT vs. contrast-enhanced CT in the staging and survival of patients with clinical stage I and II non-small cell lung cancer: a 10-year follow-up study
Jun-Tao Lin, Xiang-Meng Li, Wen-Zhao Zhong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 1, 2017
Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong, Wen-Zhao Zhong, Xu-Chao Zhang, et al.
Signal Transduction and Targeted Therapy
|
December 6, 2023
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study
Si-Yang Liu, Song Dong, Xue-Ning Yang, et al.
Signal Transduction and Targeted Therapy
|
February 23, 2023
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial
Wen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen, et al.
Page
of 15
Search research articles
Search
Showing results (121-130 of 141) with videos related to
Sort By:
Page
of 15
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 12, 2017
Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies
Zhong-Yi Dong, Chao Zhang, Yu-Fa Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 30, 2018
Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation
Shan Su, Zhong-Yi Dong, Zhi Xie, et al.
NPJ Precision Oncology
|
September 19, 2022
Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis
Chao Zhang, Hua-Fei Chen, Shi Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2025
Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer
Jia-Tao Zhang, Si-Yang Liu, Xuan Gao, et al.
JTO Clinical and Research Reports
|
January 6, 2025
Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for <i>EGFR</i>-Mutated NSCLC After Complete Resection
Song Dong, Bingfa Yan, Si-Yang Liu, et al.
Frontiers in Oncology
|
October 31, 2022
Deep learning-based growth prediction for sub-solid pulmonary nodules on CT images
Ri-Qiang Liao, An-Wei Li, Hong-Hong Yan, et al.
Annals of Nuclear Medicine
|
December 25, 2023
Impact of preoperative [<sup>18</sup>F]FDG PET/CT vs. contrast-enhanced CT in the staging and survival of patients with clinical stage I and II non-small cell lung cancer: a 10-year follow-up study
Jun-Tao Lin, Xiang-Meng Li, Wen-Zhao Zhong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 1, 2017
Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong, Wen-Zhao Zhong, Xu-Chao Zhang, et al.
Signal Transduction and Targeted Therapy
|
December 6, 2023
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study
Si-Yang Liu, Song Dong, Xue-Ning Yang, et al.
Signal Transduction and Targeted Therapy
|
February 23, 2023
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial
Wen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen, et al.
Page
of 15